Peer-influenced content. Sources you trust. No registration required. This is HCN.

Monthly Prescribing Reference (MPR)AstraZeneca Will Withdraw Leukemia Drug Lumoxiti From US Market

The decision to remove Lumoxiti from the US market was attributable to its extremely poor clinical uptake because there were other treatment choices available, according to AstraZeneca’s letter to healthcare professionals. Its limited uptake may also have been caused by the complicated administration, the requirement for toxicity prophylaxis, and the need for safety monitoring. The elimination has nothing to do with the drug’s efficacy or safety.

The Healthcare Communications Network is owned and operated by IQVIA Inc.

Click below to leave this site and continue to IQVIA’s Privacy Choices form